CLIMB BIO INC (CLYM) Stock Price & Overview
NASDAQ:CLYM • US28658R1068
The current stock price of CLYM is 7.28 USD. Today CLYM is up by 2.68%. In the past month the price increased by 41.36%. In the past year, price increased by 395.24%.
CLYM Key Statistics
- Market Cap
- 496.35M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.76
- Dividend Yield
- N/A
CLYM Stock Performance
CLYM Stock Chart
CLYM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CLYM. When comparing the yearly performance of all stocks, CLYM is one of the better performing stocks in the market, outperforming 99.52% of all stocks.
CLYM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLYM. While CLYM has a great health rating, there are worries on its profitability.
CLYM Earnings
CLYM Forecast & Estimates
13 analysts have analysed CLYM and the average price target is 11.66 USD. This implies a price increase of 60.13% is expected in the next year compared to the current price of 7.28.
CLYM Groups
Sector & Classification
CLYM Financial Highlights
Over the last trailing twelve months CLYM reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 64.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.84% | ||
| ROE | -28.67% | ||
| Debt/Equity | 0 |
CLYM Ownership
CLYM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.26 | 417.437B | ||
| AMGN | AMGEN INC | 16.83 | 204.229B | ||
| GILD | GILEAD SCIENCES INC | 16.62 | 183.894B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.95 | 83.255B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.86 | 43.24B | ||
| INSM | INSMED INC | N/A | 31.965B | ||
| NTRA | NATERA INC | N/A | 28.775B | ||
| BIIB | BIOGEN INC | 12.48 | 27.876B | ||
| MRNA | MODERNA INC | N/A | 22.581B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.41 | 21.486B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.053B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.749B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLYM
Company Profile
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Company Info
CLIMB BIO INC
20 William Street, Suite 145
Wellesley Hills MASSACHUSETTS US
Employees: 17
Phone: 18668572596
CLIMB BIO INC / CLYM FAQ
What does CLYM do?
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Can you provide the latest stock price for CLIMB BIO INC?
The current stock price of CLYM is 7.28 USD. The price increased by 2.68% in the last trading session.
Does CLIMB BIO INC pay dividends?
CLYM does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLYM stock?
CLYM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is CLIMB BIO INC (CLYM) stock traded?
CLYM stock is listed on the Nasdaq exchange.